Psilocybin therapy sessions for PTSD are mostly silent, study finds
New research indicates that psilocybin treatment for PTSD involves very little talking. Instead of traditional psychotherapy, data suggests patients benefit most from the quiet, unobtrusive presence of support staff.
A recent study in the Journal of Psychopharmacology reveals that during high-dose psilocybin treatment sessions for PTSD, participants and support staff spend most of their time in silence. Psilocybin, a psychoactive compound found in "magic" mushrooms, has been explored as a potential treatment for mental health conditions like PTSD.
Typically administered in a controlled setting with trained support staff, the treatment relies on quiet, unobtrusive presence rather than active talk therapy. The researchers analyzed data from a clinical trial involving 22 adult participants with PTSD and moderate to severe symptoms. After receiving a single 25-milligram dose of COMP360 psilocybin, most participants experienced a clinically significant reduction in symptoms and found the treatment preferable to previous therapies.
The immediate impact of the treatment stood out to the researchers, challenging the misconception that patients undergo traditional talk therapy while under the drug's influence.
Brief written by urgent.news from PsyPost's own syndicated text. Machine-written — it may contain errors, so check the original before relying on it.
